1. Introduction {#sec0005}
===============

With the global outbreak of coronavirus disease (COVID-19), laboratory-confirmed cases have increased explosively, with 227,368 deaths as of April 29, 2020 ([@bib0050]). A significant proportion of symptomatic patients required medical care, and some required specialized intensive care management that is overwhelming the health care system. Given the acute shortage of ventilators and personal protective equipment, there is a desperate need for therapy against the virus SARS CoV-2 - the pathogen for COVID-19 ([@bib0030]). Among the different medications that are under trial, two antimalarial drugs- chloroquine and hydroxychloroquine have received substantial public attention because of positive results from small studies and media coverage([@bib0015]; [@bib0045]). Chloroquine (4-amino quinolone) is prescribed for treatment and chemoprophylaxis against malaria, while hydroxychloroquine is used to treat inflammatory conditions like lupus. A quick search in the clinicaltrials.gov with the term chloroquine or hydroxychloroquine for COVID-19 yielded over 30 studies as of early April 2020. Despite the lack of any substantial evidence to support efficacy, given the present crisis, many academic centers and physicians have incorporated these medications into their therapeutic armamentarium against COVID-19 ([@bib0015]). The package insert for chloroquine and hydroxychloroquine states that "patients with a history of epilepsy should be advised about the risk of chloroquine or hydroxychloroquine provoking seizures." Understandably this statement has stirred up increased questions and anxiety in the epilepsy community about the safety of chloroquine or hydroxychloroquine in persons with epilepsy. A preclinical study suggests that chloroquine can elicit seizures in a dose-related manner by inhibiting GABAergic neurotransmission ([@bib0005]). In preclinical studies, a lower dose (1−5 mg/kg) of chloroquine prevents seizures, while a higher dose (10−50 mg/kg) had pro-convulsant effects ([@bib0040]). In contrast to chloroquine, hydroxychloroquine has a lower incidence of CNS effects. The goal of this systematic review is to assess the published literature for seizure risk with chloroquine therapy in persons with and without epilepsy.

2. Methods {#sec0010}
==========

This study was performed in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. PubMed (1970 to March 27, 2020) and the Embase (1970 to March 27, 2020) were searched with the terms chloroquine or hydroxychloroquine and seizure, epilepsy, convulsions, or status epilepticus. Only published abstracts and literature in English were reviewed. Inclusion criteria were any case study or series, and clinical trials reporting seizure or status epilepticus with chloroquine or hydroxychloroquine. Exclusion criteria were overdose or poisoning from chloroquine, animal studies, and reports of cardiac or neuropsychiatric adverse effects. Data extracted from the reports were -age, sex of study populations, the dosage of medication if available, and reported comorbidities. We reviewed the reported medication dosage to confirm that the adverse effects were related to an overdose. The level of evidence was graded between I-IV ([@bib0010]).

The adverse drug reaction of interest is a seizure or status epilepticus. For each selected study, the authors reviewed the entire manuscript and classified the adverse drug reaction as either-- a) dose-related, b) non-dose related, c) dose-related and time-related, d)time-related, e) withdrawal or f) unexpected failure of therapy ([@bib0025]).

3. Results {#sec0015}
==========

Only eleven out of 31 studies were deemed eligible for systematic analysis. Preclinical studies or reports of chloroquine or hydroxychloroquine poisoning, cardiovascular and neuropsychiatric complications were excluded. For chloroquine, eligible studies were- one prospective study(n = 109), two case series(n = 6), and six case reports. For hydroxychloroquine, there was one prospective observational study (n = 631) and one case report ([Table 1](#tbl0005){ref-type="table"} ).Table 1Characteristics of nine studies (six case reports, two case series, and one clinical trial).Table 1Type of Adverse ReactionType of Study, level of evidencePatient comorbiditiesDrug/doseReason for prescript-tionSeizures or status epilepticus (SE)Country reportedReferencesNon dose relatedCase Report, IV49 yo, F, SLEC, 250 mg/dX 30 dSLEmultiple FIAS X24 hrsPoland2018. Krzeminski P, Lesiak A, Narbutt J.PMID: 30,206,460Non dose relatedCase Report, IV14 yo, F, SLEC, 500 mg/dSLEone BTC szVenezuela2004 Tristano AG, Falcón L, Willson M, de Oca IM PMID: 14,740,170dose relatedCase Report, IV30 yo,M, healthyC, 1gm/d X4 dPpxone BTC szUK2016 Martin AN, Tsekes D, White WJ, Rossouw D. PMID: 27,005,796Non dose relatedCase Report, IV35 yo,M, healthySavarine (C 100 mg + Proguanil 200 mg) -2 dosesPpxone BTC szFrance2000. Schiemann R, Coulaud JP, Bouchaud O. PMID: 11179947.Non dose relatedCase Series, IV40 yo M, healthyMaloprim (C 400 mg + Dapsone 100 mg + Pyrimthemine 12.5 mg) 1 tab/wk X 4 wksPpxtwo BTC szUK1988, Fish DR, Espir ML. PMID: 3,139,18626 yo F, generalized epilepsyMaloprim (C 400 mg + Dapsone 100 mg + Pyrimthemine 12.5 mg) 1 tab/wk X 3 wksPPxone BTC szUK49 yo F, focal epilepsyC 400 mg /d X 1 dPpxprolonged BTC szUKNon dose relatedCase eport, IV42 yo, M, LeprosyC 450 mg/d x 8 dENL (Leprosy)two BTC szsNigeria1998 Ebenso BE. PMID: 9,715,604Non dose relatedProspective study during therapeutic clinical trial, IIN = 109; 9 mo-13 y, cerebral malariadose unknown, study correlated seizure with serun level of C and a metabolitePpx54 % szs, 9% SEKenya2000. Crawley J, Kokwaro G, Ouma D, Watkins W, Marsh K. PMID: 11,169,275Non dose relatedCase Series, IV28 yo, F, SLEC 200 mg/d X 180dSLEone BTC szNetherlands1992. Luijckx GJ, De Krom MC, Takx-Kohlen BC. PMID: 1,344,76521,yo, M, healthyC 300 mg /week X 2moPpxtwo BTC sz23 yo, M, h/o one szC 300 mg /week X 2moPpxone BTC szNon dose relatedCase Report, IV69 = 8 yo, F, healthyC 100 mg/d X12 dPpxNCSESwitzerland1995. Mülhauser P, Allemann Y, Regamey C.PMID: 7,762,925Non dose relatedCase Report,IV17, yo,F, h/o, SLE, focal epilepsyHC 200 mg/d X14 dSLEFirst onset BTC. prior h/o FIAS only.Italy2000 Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG.PMID: 11,149,659Not applicableProspective observational study, IIN = 600 adults with newly diagnosed lupus and no prior h/o seizureHC- specific dose not mentioned in the studySLE6.7 % (40) participants had a seizure after the diagnosis of SLE. Seizure details not mentioned in the manuscriptUSA2008. Andrade RM, Alarcon GS, Gonzalez LA et al. PMID: 17,875,548[^1]

3.1. Risk in healthy individuals {#sec0020}
--------------------------------

### 3.1.1. Chloroquine {#sec0025}

Pooled data revealed five healthy adults (all case reports and series) had a convulsive seizure after taking chloroquine for primary prophylaxis against malaria. One of the individuals had speech difficulties secondary to non-convulsive status epilepticus. The dose ranged between 100 mg--400 mg per day except for one individual who had a seizure after ingesting 1 gm chloroquine that was prescribed by a non-professional provider. In one individual, the EEG revealed generalized spike-wave epileptiform discharges, thereby suggesting underlying undiagnosed generalized epilepsy.

3.2. Risk in individuals with non-neurological illness {#sec0030}
------------------------------------------------------

### 3.2.1. Chloroquine {#sec0035}

Four adults (all case reports and series) had a convulsive seizure after taking therapeutic chloroquine for leprosy or lupus. The dose ranged between 200−500 mg/day. Two subjects in the case series had multiple laboratory investigations, including CSF analyses, and EEG that failed to identify any alternative etiology.

### 3.2.2. Hydroxychloroquine {#sec0040}

A multi-center prospective observational study evaluating predictors of time-to-seizure occurrence in patients with newly diagnosed lupus (N = 600) confirmed a longer latency to seizure occurrence with the use of hydroxychloroquine thereby suggesting that the medication can protect against the development of seizure. Seizures were present in 6.7 % (40) of the participants.

3.3. Risk in individuals with neurological illness, including epilepsy {#sec0045}
----------------------------------------------------------------------

### 3.3.1. Chloroquine {#sec0050}

To investigate the relationship between blood levels of chloroquine (used as prophylaxis), its metabolite desethylchloroquine, and seizures in children (N = 109, 9 months-13 years) with cerebral malaria, the investigators took advantage of a double-blinded randomized control trial where intramuscular phenobarbital (20 mg/kg) or placebo was given to prevent seizures. 54 % (59 out of 109) of children had seizures following cerebral malaria. There was no correlation between seizure and blood level of chloroquine or desethylchloroquine ([@bib0020]). Three case studies documented seizure following chloroquine prophylaxis (300−400 mg/day) in persons with epilepsy.

### 3.3.2. Hydroxychloroquine {#sec0055}

One young woman with a history of focal epilepsy and lupus had a tonic-clonic seizure for the first time following two weeks intake of therapeutic hydroxychloroquine 200 mg/day (5 mg/kg). Anti-seizure medications were unchanged, and laboratory investigations ruled out acute exacerbation of lupus. Following discontinuation of hydroxychloroquine, she had no further tonic-clonic seizures during follow up although focal seizures continued.

4. Discussion and conclusion {#sec0060}
============================

Both chloroquine and hydroxychloroquine have been used for over a decade in chemoprophylaxis against malaria and to treat lupus. Although the package insert states an increased risk of seizure, the systematic review highlights that such a statement is not supported by any class I studies but rather by anecdotal case reports and case series. Two clinical trials failed to demonstrate an increased risk of seizures with these medications.

The goal of this review was not to evaluate if chloroquine or hydroxychloroquine is an effective therapy against COVID-19. Clinical trials are ongoing, and many centers are offering the medication either through a clinical trial or as an off-label therapy. Of note, a recent observational study failed to establish the benefit of hydroxychloroquine against COVID-19 ([@bib0035]). Many of our epilepsy patients reside at a group home or facility and are at risk of contracting SARS CoV-2 virus. The evidence evaluating a link between chloroquine or hydroxychloroquine and seizure is insufficient to suggest a significant correlation. Clinicians, therefore, need to understand that data regarding this specific topic is limited to case series and case reports. There is no substantial evidence to suggest that these medications can increase seizure risk.

Appendix A. Supplementary data {#sec0070}
==============================

The following is Supplementary data to this article:

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eplepsyres.2020.106399>.

[^1]: F = female, M = male, C = chloroquine, HC = hydroxychloroquine, Ppx = prophylaxis, SLE = systemic lupus erythematous, ENL = erythema nodosum leprosum, FIAS = focal impaired awareness seizure, BTC = bilateral tonic-clonic seizure, CSF = cerebrospinal fluid.
